Provided by Tiger Trade Technology Pte. Ltd.

Dermata Therapeutics Inc

1.21
+0.02001.68%
Post-market: 1.440.2297+18.98%18:10 EDT
Volume:2.09M
Turnover:2.82M
Market Cap:3.43M
PE:-0.10
High:1.25
Open:1.19
Low:1.17
Close:1.19
52wk High:23.70
52wk Low:1.11
Shares:2.84M
Float Shares:1.98M
Volume Ratio:28.78
T/O Rate:105.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.1295
EPS(LYR):-80.3223
ROE:-203.36%
ROA:-96.45%
PB:0.87
PE(LYR):-0.02

Loading ...

Jun 22, 2022

Major Issues Report

8-K - Current report
May 17, 2022

Major Issues Report

8-K - Current report
May 16, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 16, 2022

Major Issues Report

8-K - Current report
May 11, 2022

Correspondence

CORRESP [Cover] - Correspondence
May 05, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
May 04, 2022

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Apr 25, 2022

Major Issues Report

8-K - Current report
Mar 28, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 28, 2022

Major Issues Report

8-K - Current report
Mar 02, 2022

Major Issues Report

8-K - Current report
Feb 07, 2022

[Amend]Public Prospectus

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
Feb 04, 2022

Public Prospectus

S-1 - General form for registration of securities under the Securities Act of 1933
Feb 04, 2022

Major Issues Report

8-K - Current report
Feb 04, 2022

[Supp]Public Prospectus

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Jan 13, 2022

Major Issues Report

8-K - Current report
Dec 10, 2021

Major Issues Report

8-K - Current report
Dec 10, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Nov 26, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Sep 01, 2021

Major Issues Report

Dermata Therapeutics, Inc.